Clinical Trial: NCT03952078
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Corvus Pharmaceuticals, Inc. |
| Information Provided By: | Corvus Pharmaceuticals, Inc. |
| Last Update Posted: | 2025-04-16 |
Study Overview
Brief Summary
This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug.
Official Title
A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma
Conditions
T-cell Lymphoma
Intervention / Treatment
- Drug: CPI-818
Other Study ID Numbers
- CPI-818-001
Start Date (Actual)
2019-05-03
Primary Completion Date (Estimated)
2026-04-30
Study Completion Date (Estimated)
2026-04-30
Enrollment (Estimated)
151
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Corvus Pharmaceuticals, Inc. |
| Information Provided By: | Corvus Pharmaceuticals, Inc. |
| Last Update Posted: | 2025-04-16 |
Study Overview
Brief Summary
This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug.
Official Title
A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma
Conditions
T-cell Lymphoma
Intervention / Treatment
- Drug: CPI-818
Other Study ID Numbers
- CPI-818-001
Start Date (Actual)
2019-05-03
Primary Completion Date (Estimated)
2026-04-30
Study Completion Date (Estimated)
2026-04-30
Enrollment (Estimated)
151
Study Type
Interventional
Phase
Phase 1